The pharmaceutical firm has committed a "significant" amount to the latest fund to be raised by investment firm LSP as part of a strategic collaboration agreement.
US-based pharmaceutical company Bristol-Myers Squibb Company agreed on Tuesday to make a “significant investment” in LSP 5, the latest fund to be raised by healthcare investment firm LSP.
The capital will be provided as part of a strategic collaboration whereby the firms will partner to seek out European technologies and products in areas of unmet medical need, including immuno-oncology.
LSP is headquartered in the Netherlands, with offices in Germany and the USA. Immuno-oncology is currently its biggest focus, but the…
